AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be ...

The Biologics License Application for tozorakimab 300mg, administered once every four weeks, has been accepted for Priority Review by the US Food and Drug Administration as an add-on maintenance ...

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca office in San Francisco, Calif., on Nov. 15, 2020. AstraZeneca is terminating a Phase 3 study of its experimental ...

AstraZeneca stock drew fresh attention on September 9, 2026, as RBC set a GBP 145.00 target and highlighted pipeline strength ...

I'm initiating coverage on AstraZeneca (AZN) and setting it at a "Strong Buy" rating. The reason why is because the company was able to report massive growth in revenue in Q1 of 2026. During this ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Monday - Friday, 6:00 - 7:00 PM ET AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the company develop medicines faster, identify promising drug targets, and improve the odds of ...